Boryung Pharmaceutical Receives Additional Approval for Hypertension Drug to Reduce Proteinuria

[Asia Economy Reporter Cho Hyun-ui] Boryung Pharmaceutical announced on the 6th that its hypertension treatment drug 'Kanarb' (active ingredient Pimasartan) has received approval from the Ministry of Food and Drug Safety for an additional indication.

The newly acquired indication for Kanarb is "as a treatment for hypertension, reduction of proteinuria in patients with type 2 diabetic chronic kidney disease accompanied by hypertension."

Boryung Pharmaceutical conducted a study involving 301 patients with type 2 diabetic chronic kidney disease accompanied by hypertension, administering Kanarb to 150 patients and Losartan to 151 patients, then compared the proteinuria reduction effects at 24 weeks.

As a result, Kanarb demonstrated proteinuria reduction effects equivalent to Losartan, which is used for kidney disease in type 2 diabetic patients.

Through another study, Kanarb also secured safety and efficacy when prescribed to elderly patients over 70 years old. Accordingly, the phrase "This drug has no experience of administration to elderly patients over 70 years old" was removed from the precautions for use.

Ahn Jae-hyun, CEO of Boryung Pharmaceutical, stated, "We will provide new treatment options for elderly hypertension patients and patients with type 2 diabetic chronic kidney disease accompanied by hypertension."

This content was produced with the assistance of AI translation services.